Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma
{{output}}
Relapsed and refractory (r/r) T-cell lymphoblastic lymphoma (T-LBL) is a highly lethal disease, with no effective treatment options. Daratumumab, an anti-CD38 human IgG1κ monoclonal antibody has been used as single agent in CD38 positive r/r T-LBL. We adminis... ...
